AstraZeneca to pay $425 million to settle Nexium, Prilosec litigation in US

October 3, 2023
News
37 secs read

Source: Financial Express

The agreements effectively resolve all pending claims filed against the company for failing to warn patients about the risk of contracting chronic kidney disease and related issues

Pharma major AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations against prescription-only acid-reflux medicine Nexium and heartburn drug Prilosec in the United States.

According to a report by news agency Reuters, the agreements effectively resolve all pending claims filed against the company for failing to warn patients about the risk of contracting chronic kidney disease and related issues.

There was one exception in Louisiana, AstraZeneca said the trial for which is scheduled in April next year. The company added that it has taken a provision for the settlement payment.

Pharmaways

Pharmaways Global Private Limited is a company established in 2022. Headed by a group of professionals with over 25 years of experience. A team of professionals who have excelled in their respective fields of Pharma, Legal & Information Technology. We have global exposure and hands-on experience of the global Pharma industry. We are in pursuit of bringing the global Pharma Industry on a platform where they can connect, collaborate and work towards mutual growth. We have taken a step into the future by innovating a technology that will help global Pharma players to empower, excel and accelerate in their business. A platform that has been developed exclusively for the Pharma fraternity. We are a New Delhi based company with overseas offices in America and the United Kingdom.